View Post

Alpha-TEA and Concurrent Trastuzumab Under Exploration in Refractory HER2+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Brittany Cote From: William R. Gwin III, MD, discusses the ongoing trial examining this novel combination and provided insight into the next steps for this research. Concurrent treatment with α-tocopheryloxyacetic acid (TEA) and trastuzumab (Herceptin) could possess the potential to induce clinical activity and augment type 1 (Th1) antitumor immunity in patients with HER2-positive metastatic breast cancer who have …